Invokana® Gets New Indication in Canada to Reduce Risks with Diabetic Kidney Disease

Published on
By : dLife Editors

Health Canada has approved Invokana® (canagliflozin) as an adjunct to diet, exercise, and standard-of-care therapy, to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, and cardiovascular (CV) death in adult patients with Type 2 diabetes and diabetic nephropathy (also known as diabetic kidney disease) with albuminuria.

Diabetes is the leading cause of kidney disease in Canada; up to one in two people with diabetes will experience signs of kidney damage in their lifetime.

Diabetic kidney disease (DKD) is progressive and if left untreated, can lead to dialysis or a kidney transplant. In addition, people living with diabetic kidney disease are at high risk for heart attack and stroke.

“This is an important advancement given the increased prevalence of diabetic kidney disease in those living with Type 2 diabetes,” said Dr. Adeera Levin, Head, Division of Nephrology, Professor of Medicine, University of British Columbia, Executive Director, BC Provincial Renal Agency and CREDENCE National Lead Investigator for Canada. “With this new indication for Invokana, physicians are now able to offer a treatment option that reduces the cardiovascular and kidney risks associated with diabetic kidney disease.”

The new indication is based on results from the landmark Phase 3 CREDENCE study, the first dedicated renal outcomes study of any sodium-glucose co-transporter 2 (SGLT2) inhibitor in patients with type 2 diabetes and diabetic nephropathy.

In CREDENCE, INVOKANA® added to standard-of-care therapy demonstrated a 30 percent reduction in the risk of the primary composite endpoint, comprised of end-stage kidney disease (ESKD), doubling of serum creatinine and renal or CV death, compared to standard-of-care therapy alone.

Results also showed INVOKANA® reduced the risk of secondary CV endpoints, including a 31 percent reduction in the risk of the composite of CV death or hospitalization for heart failure, a 20 percent reduction in MACE (major adverse cardiovascular events; composite of CV death, nonfatal myocardial infarction [MI] and nonfatal stroke), and a 39 percent reduction in the risk of hospitalization for heart failure alone.

Importantly, the study showed no imbalance in lower limb amputations or bone fractures and no new safety concerns were identified in this study of high-risk renal patients.

To learn more, access the company press release below.

Janssen Pharmaceutical Companies of Johnson & Johnson


  1. Janssen Pharmaceutical Companies of Johnson & Johnson. (2020, Jan. 28). Health Canada Approves New Indication for INVOKANA®* (canagliflozin) to Reduce the Risks Associated with Diabetic Kidney Disease in Patients with Type 2 Diabetes. PR Newswire. Retrieved Jan. 29, 2020 from